We are delighted that QUELIMMUNE is now available to treat severely ill children at yet another prominent academic medical center,” said Tim Varacek, SeaStar Medical Senior Vice President, Commercial ...

SeaStar Medical plans to conduct an interim analysis at the trial’s 90-day primary endpoint with the first 100 subjects. Given the current pace of enrollment, the company anticipates a Data Safety ...